Close

Seres Therapeutics (MCRB) Reports Q1 Revenues Above Consensus

May 9, 2018 7:15 AM EDT

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of $, versus ($0.76) reported last year. Revenue for the quarter came in at $3.77 million versus the consensus estimate of $2.39 million.

Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres commented: “Seres has made significant progress in advancing our field-leading microbiome therapeutic pipeline. We continue to enroll the SER-109 Phase 3 study in patients with multiply recurrent C. difficile infection. We have had positive dialogues with FDA to support further development of SER-287 in Ulcerative Colitis and we continue to plan to initiate a next SER-287 study in mid-2018. Seres also presented important preclinical data that further elucidate how microbiome therapy impacts immune biology and checkpoint inhibitor activity. Dialogue with the FDA is ongoing regarding immuno-oncology related development plans, and we expect initiation of the SER-401 microbiome therapy clinical study later this year.”

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Management Comments

Related Entities

Earnings, FDA